We understand the many challenges you face in the development, commercialization and protection of potentially life-saving products and services in the highly-regulated US market.

We, like you, focus on the issues that are the core of your business. We work alongside you in the key areas you expect from your lawyers, and some that may surprise you. Life sciences is a broad term that touches almost every industry -- you will work with a team that collaborates regularly with lawyers from diverse areas such as finance and corporate law, intellectual property protection, tax, litigation, health care, venture technology, risk management, compliance and public policy. We individualize our client teams, to ensure that you receive innovative and commercially focused service.

As your partner, we will provide the knowledge and support you need to keep projects moving, while protecting and capitalizing on your innovations. From early R&D stages through development, clinical trials, manufacturing, and marketing and sales, you can look to us to assist with all phases of your products and services.

Need assistance with corporate governance, public offerings, venture capital investments, mergers and acquisitions, leveraged buyouts, technology transfer transactions, university spin-offs and initial financing transactions? Know that we have you covered.

Facing liability relating to sales of your products and services from private litigants or government regulators? Rely on our team for in-depth knowledge to guide you through government regulatory policies and enforcement, investigations, complex commercial disputes, pricing litigation, product liability and mass tort claims, Foreign Corrupt Practices Act claims, patent and trademark disputes, employment and ERISA issues, antitrust and competition law claims and class actions.

Wherever you find yourself in the life sciences lifecycle, our experienced lawyers can help you navigate:

• Antitrust Counseling
• Corporate Finance
• Corporate Governance
• Fraud and Abuse Counseling, Investigations and Defense
• Intellectual Property and Technology Protection
• Litigation, Arbitration, Mediation and other Dispute Resolution
• Mergers and Acquisitions
• Privacy and Security
• Product Liability
• Product Recalls
• Product-Related Legal Issues
• Regulatory Counseling
• Tax Exemption
• Venture Capital and Private Equity Counseling and Financing

Recognition

Dentons Boosts Rankings in 2015 Edition of Legal 500 US

June 11, 2015

​​​The 2015 edition of The Legal 500 US recognizes 24 Dentons practices and 75 lawyers.

57 Dentons Practices and Lawyers Ranked in The Legal 500 US

June 14, 2013

The 2013 edition of The Legal 500 US recognizes 15 Dentons practices and 42 lawyers, representing a more than 50 percent increase in total rankings in the past year. Recognition for the Firm includes "seamless extensions of clients’ teams;" "exemplary strategic and tactical leadership;" and "far above other firms, both in technical strengths and business experience."

Insights

Strategies to Help Best Prepare for the Company Deposition

May 20, 2025

Sophisticated plaintiffs’ lawyers in high stakes litigation matters often seek to use the Rule 30(b)(6) deposition as a tool to lock in testimony that they may leverage to produce outsized verdicts at trial. The use of “reptile” tactics has only served to increase this risk. To reduce the risk of such outcomes, defense counsel and the corporate deponent should attack preparation for the Rule 30(b)(6) deposition in a comprehensive manner.

How to Build a Winning Defense Case – Pretrial Strategy

February 27, 2025

Begin with the End in Mind. From the very inception of a potential high exposure case, defense counsel should begin formulating a plan for achieving victory at the end of the case, whether by motion and/or trial. When defense counsel takes this approach in a disciplined and rigorous manner, counsel optimizes the opportunity for a positive outcome.

Introduction to Dentons’ Trial Strategy Series

February 27, 2025

Over the past fifteen years, we have seen a concerning rise in "nuclear verdicts," or jury awards of $10 million or more. While this development undoubtedly benefits contingency fee plaintiffs’ lawyers, it presents significant potential adverse consequences to corporate defendants and the people they employ. This article explores the data concerning the rise in nuclear verdicts and introduces the Dentons US Trial Strategy Series.

View all insights for Life Sciences in the United States

News and Events

Recent Press Releases

Dentons Boosts Rankings in 2015 Edition of Legal 500 US

June 11, 2015

​​​The 2015 edition of The Legal 500 US recognizes 24 Dentons practices and 75 lawyers.